

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA HEALTH

China Health Technology Group Holding Company Limited

中國健康科技集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1069)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Health Technology Group Holding Company Limited (the “**Company**”) announces the unaudited condensed consolidated interim results of the Company and its subsidiaries (the “**Group**”) for the six months ended 31 December 2025 (the “**Reporting Period**”) together with the comparative figures for the six months ended 31 December 2024 (the “**Previous Period**”).

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 31 December 2025

	<i>Notes</i>	Six months ended	
		31 December	
		2025	2024
		(Unaudited)	(Unaudited)
		<i>RMB'000</i>	<i>RMB'000</i>
Revenue	4	34,393	31,112
Cost of sales		<u>(30,256)</u>	<u>(28,335)</u>
Gross profit		<u>4,137</u>	<u>2,777</u>
Investment and other income	6	376	2
Other gains	7	11,510	13,140
Selling and distribution expenses		(499)	(148)
Administrative expenses		(8,470)	(9,392)
Finance costs	8	<u>(1,798)</u>	<u>(1,337)</u>
Profit before tax	9	5,256	5,042
Income tax expense	10	(4)	(64)
Profit for the period		<u>5,252</u>	<u>4,978</u>
OTHER COMPREHENSIVE INCOME			
Items that may be subsequently reclassified to profit or loss:			
Exchange differences on translation of financial statements of foreign operations		<u>154</u>	<u>1,375</u>
Other comprehensive income for the period		<u>154</u>	<u>1,375</u>
Total comprehensive income for the period		<u>5,406</u>	<u>6,353</u>
		<i>RMB Cents</i>	<i>RMB Cents</i> (Restated)
Profit per share	12		
Basic		5.25	6.30
Diluted		<u>N/A</u>	<u>N/A</u>

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2025

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
<i>Notes</i>	<i>RMB'000</i>	<i>RMB'000</i>
NON-CURRENT ASSETS		
Property, plant and equipment	1,646	1,960
Right-of-use asset	36,350	37,743
Plantation forest assets	52,288	50,650
Plantation ginseng assets	45,167	38,400
Plantation horny goat weed assets	25,489	16,623
	160,940	145,376
	160,940	145,376
CURRENT ASSETS		
Inventories	5,987	1,480
Trade and other receivables	28,500	37,836
Deposits and prepayments	3,290	16,235
Bank balances and cash	2,601	4,490
	40,378	60,041
	40,378	60,041
CURRENT LIABILITIES		
Trade and other payables	27,962	29,029
Contract liabilities	44	11,597
Lease liabilities	355	711
Income tax payable	1,714	1,736
	30,075	43,073
	30,075	43,073
NET CURRENT ASSETS	10,303	16,968
TOTAL ASSETS LESS CURRENT LIABILITIES	171,243	162,344

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
	<i>Notes</i>	
NON-CURRENT LIABILITY		
Promissory notes payable	<u>114,357</u>	<u>115,624</u>
	<u>114,357</u>	<u>115,624</u>
NET ASSETS	<u>56,886</u>	<u>46,720</u>
Capital and reserves		
Share capital	9,553	7,853
Reserves	<u>47,333</u>	<u>38,867</u>
Total equity	<u>56,886</u>	<u>46,720</u>

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2025

1. GENERAL INFORMATION

China Health Technology Group Holding Company Limited is a public limited company incorporated in the Cayman Islands and its shares are listed on the Main Board of the Stock Exchange.

The Group is principally engaged in forestry management, ginseng plantation and trading, horny goat weed plantation and trading, health products trading and investment holding.

The functional currency of the Company is Hong Kong dollars (“**HK\$**”) while the functional currency of the subsidiaries of the Company established in the People’s Republic of China (the “**PRC**”) is Renminbi (“**RMB**”). For the purpose of presenting the consolidated financial statements, the Group adopted RMB as its presentation currency as to better reflect the financial results and performance of the main operation of the Group.

The condensed consolidated interim financial statements are unaudited but have been reviewed by the Audit Committee.

2. BASIS OF PREPARATION

The condensed consolidated interim financial statements and selected explanatory notes have been prepared in accordance with Hong Kong Accounting Standard 34 (“**HKAS 34**”) “Interim Financial Reporting” issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”) as well as the applicable disclosure requirements of Appendix D2 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”).

The condensed consolidated interim financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values.

The accounting policies and methods of computation used in the condensed consolidated interim financial statements for the six months ended 31 December 2025 are the same as those presented in the Group’s consolidated financial statements for the year ended 30 June 2025.

Going concern basis

The directors of the Company have, at the time of approving the condensed consolidated interim financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

Segment revenues and results

The following is an analysis of the Group's revenue and results by reportable segments:

For the six months ended 31 December 2025 (unaudited)

	Forestry Business <i>RMB'000</i>	Ginseng Business <i>RMB'000</i>	Horny Goat Weed Business <i>RMB'000</i>	Health Products Business <i>RMB'000</i>	Total <i>RMB'000</i>
Segment revenue	<u>7,068</u>	<u>16,776</u>	<u>-</u>	<u>10,549</u>	<u>34,393</u>
Segment profit	<u>3,856</u>	<u>4,273</u>	<u>-</u>	<u>1,272</u>	9,401
Unallocated bank interest income					3
Other unallocated expenses					(2,350)
Finance costs					<u>(1,798)</u>
Profit before tax					5,256
Income tax expense					<u>(4)</u>
Profit for the period					<u>5,252</u>

For the six months ended 31 December 2024 (unaudited)

	Forestry Business <i>RMB'000</i>	Ginseng Business <i>RMB'000</i>	Horny Goat Weed Business <i>RMB'000</i>	Health Products Business <i>RMB'000</i>	Total <i>RMB'000</i>
Segment revenue	<u>11,564</u>	<u>16,152</u>	<u>-</u>	<u>3,396</u>	<u>31,112</u>
Segment profit	<u>9,105</u>	<u>1,751</u>	<u>-</u>	<u>508</u>	11,364
Unallocated bank interest income					2
Other unallocated expenses					(4,987)
Finance costs					<u>(1,337)</u>
Profit before tax					5,042
Income tax expense					<u>(64)</u>
Profit for the period					<u>4,978</u>

Segment assets and liabilities

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
Segment assets		
Forestry Business	101,017	112,436
Ginseng Business	62,476	65,183
Horny Goat Weed Business	25,489	16,623
Health Products Business	4,243	2,718
	<hr/>	<hr/>
Total segment assets	193,225	196,960
Unallocated assets	8,093	8,457
	<hr/>	<hr/>
Consolidated assets	201,318	205,417
	<hr/> <hr/>	<hr/> <hr/>
	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
Segment liabilities		
Forestry Business	4,725	3,304
Ginseng Business	16,064	26,048
Horny Goat Weed Business	–	–
Health Products Business	–	285
	<hr/>	<hr/>
Total segment liabilities	20,789	29,637
Unallocated liabilities	123,643	129,060
	<hr/>	<hr/>
Consolidated liabilities	144,432	158,697
	<hr/> <hr/>	<hr/> <hr/>

6. INVESTMENT AND OTHER INCOME

	Six months ended 31 December 2025 (Unaudited) RMB'000	2024 (Unaudited) RMB'000
Bank interest income	3	2
Others	373	–
	<hr/>	<hr/>
Total investment and other income	376	2
	<hr/> <hr/>	<hr/> <hr/>

7. OTHER GAINS, NET

	Six months ended 31 December	
	2025 (Unaudited) RMB'000	2024 (Unaudited) RMB'000
Net gain on change in fair value less costs to sell of plantation forest assets		
– forest	7,068	11,564
– ginseng	2,598	1,576
Exchange gain	1,844	–
	<u>11,510</u>	<u>13,140</u>

8. FINANCE COSTS

	Six months ended 31 December	
	2025 (Unaudited) RMB'000	2024 (Unaudited) RMB'000
Interest on:		
– corporate bonds payable	1,691	1,200
– lease liabilities	107	137
	<u>1,798</u>	<u>1,337</u>

9. PROFIT BEFORE TAX

	Six months ended 31 December	
	2025 (Unaudited) RMB'000	2024 (Unaudited) RMB'000
Profit before tax has been arrived at after charging:		
Directors' emoluments	371	421
Other staff costs	2,091	1,107
	<u>2,462</u>	<u>1,528</u>
Total staff costs		
	<u>2,462</u>	<u>1,528</u>
Cost of timber harvested	7,068	11,564
Cost of ginseng harvested	2,598	5,380
Cost of ginseng trading	12,503	8,712
Cost of health products trading	8,087	2,679
Depreciation charge in respect of:		
– property, plant and equipment	313	113
– right-of-use assets	1,383	2,717
Short-term lease expenses	374	302
	<u>374</u>	<u>302</u>

Note:

- (i) No diluted profit per share were presented as there were no potentially dilutive ordinary share in issue during both of the periods presented.

13. TRADE AND OTHER RECEIVABLES

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
Trade receivables	24,442	33,796
Other receivables	4,058	4,040
	<u>28,500</u>	<u>37,836</u>

The Group generally allows an average credit period of 120 days (2025: 120 days) to its trade customers, where partial payment in advance is normally required. The Group does not hold any collateral over these balances. The following is an aged analysis of trade receivables, net of allowance for impairment losses, presented based on invoice dates:

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
0–90 days	17,109	25,708
91–180 days	7,333	8,088
181–365 days	–	–
Total	<u>24,442</u>	<u>33,796</u>

14. TRADE AND OTHER PAYABLES

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
Trade payables (<i>Note (i) & (ii)</i>)	2,493	5,535
Amounts due to former directors and existing shareholders	23,366	22,486
Other payables and accrued charges	2,103	1,008
	<u>27,962</u>	<u>29,029</u>

Notes:

- (i) The average credit period on purchase of goods is within 90 days. The Group has financial risk management policies in place to ensure that all payables are settled within the credit time frame.
- (ii) The following is an aged analysis of trade payables presented based on invoice dates:

	31 December 2025 (Unaudited) RMB'000	30 June 2025 (Audited) RMB'000
0-30 days	2,244	5,330
31-90 days	169	-
Over 90 days	80	205
	<hr/>	<hr/>
	2,493	5,535
	<hr/> <hr/>	<hr/> <hr/>

MANAGEMENT DISCUSSION AND ANALYSIS

Business and Operational Review

The Group is principally engaged in the businesses of forestry management, ginseng plantation and trading, horny goat weed plantation and trading, health products trading and investment holding.

Forestry Management Business

The Group has been engaging in the forestry management business since 2013. Revenue generated from the Group's forestry management business is mainly derived from sales of timber logs which are harvested from the Group's forests. The Group recognises revenue from timber log sales when control of the relevant goods is transferred to the customers.

As at the date of this announcement, all of the forest lands owned by the Group are located in the Sichuan Province in the PRC.

The table below sets forth all forest land owned by the Group:

Name	Location	Size	Type of timber
Hengchang Forests	Muma Town, Jiange County of Sichuan Province	21,045 Chinese Mu (equivalent to 1,403 hectares)	Cypress
Kunlin Forests	Zhengxing Town, Jiange County of Sichuan Province	9,623 Chinese Mu (equivalent to 642 hectares)	Cypress
Senbo Forests	Yixing Town, Jiange County of Sichuan Province	13,219 Chinese Mu (equivalent to 881 hectares)	Cypress
Ruixiang Forests	Longyuuanzhen, Houshixiang and Dianzixiang Town, Jiange County of Sichuan Province	30,653 Chinese Mu (equivalent to 2,044 hectares)	Cypress
Wantai Forests	Kaifeng Town, Yingshui Village, Guangping Village, and Zheba Village, Jiange County of Sichuan Province	42,814 Chinese Mu (equivalent to 2,854 hectares)	Cypress

In December 2025, the Group successfully obtained the logging permits for the calendar year of 2026 with logging quantity of 5,250 cubic meters in aggregate. During the Reporting Period, the Group has completed the sales of logging quantity of approximately 5,250 cubic meters and has generated logging revenue of approximately RMB7.1 million.

Ginseng Business

To fully utilise the woodland of the Group and to maximise shareholders' return, the Group has begun the plantation of ginseng in the Group's existing forests and has commenced the trading of ginseng in August 2022.

During the year ended 30 June 2023, the Group has entered into a legally-binding ginseng planting framework agreement with an independent third party supplier (the "**Supplier**") for the plantation of ginseng on the Senbo Forest. Pursuant to the said framework agreement, the Supplier will be responsible for, among others, the supply of ginseng seeds and culture medium, and provision of technical support and maintenance services (including fertilisation, weeding, insecticide and soil preparation) to the Group for a period of 10 years.

In December 2022, the Group has completed the first phrase of ginseng seeding according to its ginseng plantation plan of approximately 6 million pieces on the designated 59 Chinese Mu forest land in the Senbo Forest, which are expected to be sold in batches within 5 years. During the Reporting Period, the Group recorded the revenue in sales of self-grown ginseng of approximately RMB7.95 million (Previous Period: RMB5.38 million).

As it will take time for the Group to self-grow its inventory of aged ginseng, as well as to capture the market share and develop its customer base in the ginseng industry in the PRC, the Group has also commenced the ginseng trading business in August 2022 by purchasing aged ginseng. The Group has also entered into a long-term supply framework agreement with the Supplier to ensure the stable supply of aged ginseng. Hence, revenue currently generated from the ginseng business is derived from the sale of ginseng that are purchased from the Supplier. During the Reporting Period, the Group has recorded revenue of approximately RMB16.8 million from the ginseng business, including approximately RMB8.85 million derived from the sale of ginseng purchased from suppliers and approximately RMB7.95 million from its self-grown ginseng.

Health Products Business

The Group commenced its business in manufacturing and trading of health products since November 2024 and has opened a 150-square-foot store in Hong Kong. The store is currently selling ginseng gift boxes under our own brand name and other health products. The ginseng are sourced from outside suppliers and packaged by a third-party factory.

The Group produced ginseng gift boxes using our self-grown ginseng in 2025, which has been processed and packaged through a third-party factory according to our quality standards and formulations. We have created exquisite gift boxes under our brand to sell in the retail market. In addition to producing our own brand, we have also introduced other brands for sale in the store.

The Group aims to provide customers with high-quality health products and promote our business growth continuously. During the Reporting Period, the Group has recorded revenue of approximately RMB10.5 million from the health products business.

Prospect

In respect of the forestry management business, In December 2025, the Group has obtained the logging permits for the calendar year of 2026 with logging quantity of 5,250 cubic meters in aggregate, which is higher than the logging quantity obtained last year.

In respect of the ginseng business, to reduce reliance on the Supplier, the Group intends to gradually decrease the purchases of aged ginseng from the Supplier when it has self-grown sufficient inventory of aged ginseng. Currently, the Group successfully cultivated the first phase of ginseng and sold them every year. The ginseng plants from the plantation process shares the same genes as those supplied by the Supplier, therefore the quality of which is guaranteed. Nonetheless, the Group will conduct self-inspection from time to time and engages third-party laboratory for laboratory testing on an annual basis in order to ensure the quality of its ginseng and the nutrient content is able to meet the customer requirements.

The Group has commenced the manufacturing and trading of health products since November 2024. The business is currently focused in Hong Kong, the Group aims to expand its market into China in the future.

In June 2024, the Group has successfully planted the first batch of horny goat weed in its forest land owned by the Group and added 28 Chinese mu of horny goat weed cultivation in July 2024. It is expected the horny goat weed will be sold to customers by June 2026 and generate revenue in the future. The reason for the delayed sale is that the Group must first increase its supply of horny goat weed to secure higher-quality customers.

FINANCIAL REVIEW

Revenue

During the Reporting Period, the Company recorded a revenue of approximately RMB34.4 million (Previous Period: approximately RMB31.1 million). The Group's revenue for the Reporting Period was attributable to the revenue from the forestry business, ginseng business and health products manufacturing and trading business of the Group.

Gross Profit

The Group recorded a gross profit of approximately RMB4.1 million for the Reporting Period (Previous Period: approximately RMB2.8 million).

Selling and Distribution Expenses

The selling and distribution expenses for the Reporting Period amounted to RMB499,000 (Previous Period: RMB148,000). The selling and distribution costs were mainly attributable to advertising expense.

Administrative Expenses

The administrative expenses decreased appropriately 9.8% from approximately RMB9.4 million for the Previous Period to approximately RMB8.5 million for the Reporting Period. The decrease in administrative expenses was mainly attributable to the decrease of legal and professional fee.

Other Gains

For the Reporting Period, the Group recorded approximately RMB11.5 million other gains (Previous Period: approximately RMB13.1 million). Other gains mainly consisted of net gain on change in fair value less costs to sell of plantation forest assets of approximately RMB7.1 million.

Finance Costs

For the Reporting Period, the Group recorded finance costs of RMB1.8 million (Previous Period: approximately RMB1.3 million). The increase in finance cost was attributable to the interest of the promissory note payable.

Profit and Total Comprehensive Income for the Period

The Company recorded a profit of approximately RMB5.3 million for the Reporting Period as compared to a profit of approximately RMB5.0 million for the Previous Period. The total comprehensive income attributable for the period was RMB5.4 million for the Reporting Period as compared to the total comprehensive income of approximately RMB6.4 million for the Previous Period.

LIQUIDITY AND FINANCIAL RESOURCES

The Group generally finances its daily operations from internally generated cash flows and proceeds from restructuring. As at 31 December 2025, the Group had total assets of approximately RMB201.3 million and net assets of approximately RMB56.9 million. The Group's cash and bank balances as at 31 December 2025 amounted to approximately RMB2.6 million. As at 31 December 2025, there was no unutilised banking facilities (30 June 2025: nil).

PLEDGE ON ASSETS

As at 31 December 2025, there was no pledge of assets of the Group (30 June 2025: nil).

CONTINGENT LIABILITIES

Save as disclosed in this announcement, the Group did not have any significant contingent liabilities as at 31 December 2025.

FOREIGN EXCHANGE EXPOSURE AND RELATED HEDGES

The Group's transactions are mainly denominated in Hong Kong dollars and RMB. Therefore, the Group is exposed to exchange rate risk. The majority of the Group's cash and bank balances are also denominated in these two currencies. During the Reporting Period, the Group did not experience significant exposure to exchange rate and interest rate fluctuations. Accordingly, the Group has not implemented any foreign currency hedging policy at the moment. However, the management of the Group will constantly review the economic situation, development of each business segment and the overall foreign exchange risk profile, and will consider appropriate hedging measures in the future when necessary.

GEARING RATIO

The gearing ratio of the Group, which is calculated as total liabilities divided by total assets of the Group was approximately 71.7% as at 31 December 2025 (30 June 2025: 77.3%).

CAPITAL STRUCTURE

The share capital of the Company comprises only ordinary shares. As at 31 December 2025, the total number of the ordinary shares of the Company in issue was 102,924,220 shares (30 June 2025: 859,242,204 shares). The total equity attributable to owners of the Company was approximately RMB56.9 million (30 June 2025: approximately RMB46.7 million).

CAPITAL COMMITMENTS

The Group has no capital commitments as at 31 December 2025 (30 June 2025: nil).

SIGNIFICANT INVESTMENTS HELD AND MATERIAL ACQUISITIONS AND DISPOSAL OF SUBSIDIARIES

The Group had no material acquisitions or disposals during the Reporting Period and up to the date of this announcement.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

The Group had no future plans for material investments or capital assets as at 31 December 2025.

SHARE CONSOLIDATION AND CHANGE IN BOARD LOT SIZE

On 27 May 2025, the Board proposed to implement the share consolidation on the basis that every ten (10) issued and unissued shares of HK\$0.01 each in the share capital of the Company be consolidated into one (1) consolidated share of HK\$0.1 each (the “**Share Consolidation**”).

Pursuant to an ordinary resolution passed on 4 July 2025, the Share Consolidation was approved by the Shareholders and became effective on 8 July 2025. Since then, (i) the total number of issued shares of the Company was adjusted from 859,242,204 to 85,924,220; and (ii) the board lot size for trading on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) changed from 16,000 to 10,000.

For further details, please refer to the announcement of the Company dated 27 May 2025, the circular of the Company dated 13 June 2025 and the poll results announcement of the Company dated 4 July 2025.

SHARE PLACEMENT

On 22 July 2025, the Company announced that it has conditionally agreed to place through Cheong Lee Securities Limited, on a best-effort basis, up to an aggregate of 17,000,000 new shares of the Company at the price of HK\$0.28 per placing share (the “**Placing**”) to raise up to approximately HK\$4.63 million (after deduction of placing commission and other expenses of the Placing), representing approximately 16.52% of the then issued share capital of the Company as enlarged by the allotment and issue of all the placing shares. The Placing was placed to not less than six independent places at the placing price of HK\$0.28 per placing share on 1 August 2025.

The net proceeds (after deduction of placing commission and other expenses of the Placing) raised from the 2025 Placing amounted to approximately HK\$4.63 million were intended to replenish the general working capital of the Group. As at 31 December 2025, the Company has fully utilised the 2025 Placing proceeds as intended.

For further details, please refer to the announcements of the Company dated 22 July 2025 and 1 August 2025.

EVENTS AFTER REPORTING PERIOD

Appointment of Directors

Ms. Cao Xiying has been appointed as an executive Director with effect from 15 January 2026.

Mr. Li Liangjie has been appointed as an independent non-executive Director with effect from 15 January 2026. Following his appointment, Mr. Li Liangjie has also been appointed as a member of each of the audit committee of the Board (the “**Audit Committee**”), the remuneration committee of the Board and the nomination committee of the Board. For more details, please refer to the announcement of the Company dated 15 January 2026.

Save as disclosed above and in this announcement, there was no other material event which could have material impact to the Group’s operating and financial performance after the Reporting Period and up to the date of this announcement.

EMPLOYEES AND REMUNERATION POLICIES

As at 31 December 2025, the Group had a total of 29 employees and management personnel as compared to 27 employees and management personnel as at 31 December 2024. Total staff costs for the Reporting Period, including Directors’ remuneration, amounted to approximately RMB0.4 million (Previous Period: RMB1.4 million). The Group’s remuneration policy is in line with the prevailing market standards and is determined on the basis of performance and experience of individual employee. Other employee benefits include contributions to social insurance scheme.

INTERIM DIVIDEND

The Directors do not recommend the payment of an interim dividend for the Reporting Period (Previous Period: nil).

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any listed shares of the Company (including treasury shares (as defined in the Listing Rules, if any) during the Reporting Period.

COMPETING INTEREST

During the Reporting Period, the Directors were not aware of any business or interest of the Directors or any substantial shareholder (as defined under the Listing Rules) of the Company and their respective associates that had competed or might compete with the business of the Group and any other conflicts of interests which any such person had or might have with the Group.

DIRECTORS' INTERESTS IN TRANSACTIONS, ARRANGEMENTS OR CONTRACTS

Save for the service contracts and letters of appointment entered into with the respective Directors, no contract of significance to which the Company or any of its subsidiaries was a party and in which a director had a material interest, whether directly or indirectly, subsisted at the end of the Reporting Period or any time during the Reporting Period.

COMPLIANCE WITH THE CODE ON CORPORATE GOVERNANCE PRACTICE

The Company has adopted all the code provisions (the “**Code Provisions**”) contained in the Corporate Governance Code (the “**CG Code**”) as set out in Appendix C1 to the Listing Rules as the Company’s code on corporate governance. The Board shall review and update its code of corporate governance from time to time to ensure its continuous compliance with the CG Code. Pursuant to Code Provision C.2.1, save as the roles of Chairman and Chief Executive Officer are held by the same person, Ms. Bu Xue, effective since 31 December 2025. The Board considers this arrangement appropriate given her extensive experience, and it will continue to monitor the structure. Throughout the Reporting Period, in the opinion of the Board, the Company complied with all the Code Provisions contained in the CG Code and, where appropriate, adopted the Recommended Best Practices set out in the CG Code.

The Company periodically reviews its corporate governance practices to ensure they continue to meet the requirements of the Code Provisions contained in the CG Code.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted a code of conduct regarding securities transactions by the Directors on terms no less exacting than the required standard of dealings as set out in Appendix C3 – Model Code for Securities Transactions by Directors of Listed Issuers of the Listing Rules. Having made specific enquiry with all the Directors, the Company confirmed that all the Directors have complied with the code of conduct and the required standard of dealings concerning securities transactions by the Directors for the Reporting Period.

AUDIT COMMITTEE

The Company has established the audit committee (the “**Audit Committee**”) in accordance with the requirements of the Code Provisions as set out in Appendix C1 of the Listing Rules. As at the date of this announcement, the Audit Committee has three members comprising our three independent non-executive Directors, namely Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie. Mr. Chau Wing Nam has been appointed as the chairman of the Audit Committee.

The Audit Committee focuses not only on the impact of the changes in accounting policies and practices but also on the compliance with accounting standards, the Listing Rules and the legal requirements in the review of the Company’s interim and annual reports.

The Group’s unaudited interim financial statements for the Reporting Period have been reviewed by the Audit Committee.

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This interim results announcement is published on the website of the Stock Exchange at www.hkexnews.hk and the Company’s website at www.01069.com.cn. The interim report for the Reporting Period of the Company containing all the information required by the Listing Rules will be despatched to the Shareholders by the means of receipt of communications they selected and will be published on the above websites in due course.

By order of the Board
China Health Technology Group Holding Company Limited
Bu Xue
Chairman and Executive Director

Hong Kong, 27 February 2026

As at the date of this announcement, the Board comprises Ms. Bu Xue and Ms. Cao Xiying as the executive Directors; and Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie as the independent non-executive Directors.